iTeos Therapeutics in a pharma licensing deal with Pfizer will license the rights to three of its anti-tumor compounds for $24 million, as it attempts to get the backing of a global pharmaceutical firm for the development and commercialization of its IDO1 and TDO2 drug candidates.
It will also be eligible for an undisclosed amount of milestone and royalty payments.
Under the terms of the pharma licensing deal, iTeos will license its pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2) to Pfizer for development and sales.
The two companies will then collaborate on research to find new targets that play key roles in the immune system’s response to tumors.
Any new targets found will be shared by iTeos and Pfizer for further independent or collaborative development, said the firms.
Both IDO1 and TDO2 are enzymes that break down the amino acid tryptophan and are often expressed in certain types of cancers.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends